SK12697A3 - Polymorphs of lesopitron dichlorochloride and its hydrated forms, preparation method and compositions containing them - Google Patents

Polymorphs of lesopitron dichlorochloride and its hydrated forms, preparation method and compositions containing them Download PDF

Info

Publication number
SK12697A3
SK12697A3 SK126-97A SK12697A SK12697A3 SK 12697 A3 SK12697 A3 SK 12697A3 SK 12697 A SK12697 A SK 12697A SK 12697 A3 SK12697 A3 SK 12697A3
Authority
SK
Slovakia
Prior art keywords
polymorph
dihydrochloride
hydrate
lesopitron
lesopitron dihydrochloride
Prior art date
Application number
SK126-97A
Other languages
English (en)
Slovak (sk)
Inventor
Roses P Lupon
Navarro J Tomas
Torres S Puig
Constansa J Frigola
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of SK12697A3 publication Critical patent/SK12697A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK126-97A 1995-05-31 1996-05-29 Polymorphs of lesopitron dichlorochloride and its hydrated forms, preparation method and compositions containing them SK12697A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES09501086A ES2099031B1 (es) 1995-05-31 1995-05-31 Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
PCT/ES1996/000121 WO1996038439A1 (es) 1995-05-31 1996-05-29 Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen

Publications (1)

Publication Number Publication Date
SK12697A3 true SK12697A3 (en) 1997-07-09

Family

ID=8290585

Family Applications (1)

Application Number Title Priority Date Filing Date
SK126-97A SK12697A3 (en) 1995-05-31 1996-05-29 Polymorphs of lesopitron dichlorochloride and its hydrated forms, preparation method and compositions containing them

Country Status (29)

Country Link
US (1) US5872125A (hu)
EP (1) EP0771798A1 (hu)
JP (1) JPH10503532A (hu)
CN (1) CN1076020C (hu)
AR (1) AR003952A1 (hu)
AU (1) AU699210B2 (hu)
BG (1) BG62966B1 (hu)
CA (1) CA2196425A1 (hu)
CO (1) CO4700461A1 (hu)
CZ (1) CZ24797A3 (hu)
EE (1) EE9700067A (hu)
ES (1) ES2099031B1 (hu)
GE (1) GEP20002241B (hu)
HU (1) HUP9700284A3 (hu)
IL (1) IL118494A0 (hu)
IN (1) IN186820B (hu)
IS (1) IS4420A (hu)
MA (1) MA23883A1 (hu)
MX (1) MX9700792A (hu)
NO (1) NO310073B1 (hu)
NZ (1) NZ308110A (hu)
PL (1) PL318280A1 (hu)
RU (1) RU2178789C2 (hu)
SK (1) SK12697A3 (hu)
TR (1) TR199600455A2 (hu)
UY (1) UY24241A1 (hu)
WO (1) WO1996038439A1 (hu)
YU (1) YU32396A (hu)
ZA (1) ZA964139B (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2642759B1 (fr) * 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
FR2654621B1 (fr) * 1989-11-22 1994-09-23 Esteve Labor Dr Inhibition du syndrome d'abstinence.
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
FR2671972B1 (fr) * 1991-01-25 1995-03-03 Esteve Labor Dr Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives.
FR2673628B1 (fr) * 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .

Also Published As

Publication number Publication date
GEP20002241B (en) 2000-09-25
PL318280A1 (en) 1997-06-09
IS4420A (is) 1997-01-29
CA2196425A1 (en) 1996-12-05
WO1996038439A1 (es) 1996-12-05
AU5765096A (en) 1996-12-18
UY24241A1 (es) 1996-06-14
HUP9700284A3 (en) 1998-01-28
CN1076020C (zh) 2001-12-12
IL118494A0 (en) 1996-09-12
CZ24797A3 (en) 1997-05-14
CN1158128A (zh) 1997-08-27
AU699210B2 (en) 1998-11-26
RU2178789C2 (ru) 2002-01-27
EE9700067A (et) 1997-10-15
BG101176A (en) 1997-08-29
HU9700284D0 (en) 1997-04-28
AR003952A1 (es) 1998-09-30
NO970392D0 (no) 1997-01-29
EP0771798A1 (en) 1997-05-07
BG62966B1 (bg) 2000-12-29
IN186820B (hu) 2001-11-17
ES2099031A1 (es) 1997-05-01
MX9700792A (es) 1997-05-31
HUP9700284A2 (en) 1997-11-28
NZ308110A (en) 1997-08-22
MA23883A1 (fr) 1996-12-31
NO310073B1 (no) 2001-05-14
CO4700461A1 (es) 1998-12-29
ZA964139B (en) 1997-02-06
TR199600455A2 (tr) 1996-12-21
ES2099031B1 (es) 1997-12-01
US5872125A (en) 1999-02-16
JPH10503532A (ja) 1998-03-31
YU32396A (sh) 1999-07-28
NO970392L (no) 1997-04-01

Similar Documents

Publication Publication Date Title
DE69720719T2 (de) Mesylat des trihydrats des 5-(2-(4-(1,2-benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist
CZ301778B6 (cs) Modifikace 2-amino-4-(4-fluorbenzylamino)-1-ethoxykarbonylaminobenzenu, zpusoby jejich prípravy, jejich použití a lécivo, které je obsahuje
CZ304471B6 (cs) 1-[4-(5-kyanindol-3-yl)butyl]-4-(2-karbamoylbenzofuran-5-yl)piperazin hydrochlorid anhydrát v krystalické formě IV, způsob jeho přípravy a farmaceutická kompozice s jeho obsahem
JPS63280081A (ja) 置換イミダゾリル−アルキル−ピペラジンおよび−ジアゼピン誘導体
MX2008002541A (es) Formas de cristal delta y epsilon de mesilato de imatinib.
DE69330497T2 (de) Chinazolin-derivate
EA002970B1 (ru) Новые кристаллические формы противовирусного соединения бензимидазола, способ их получения, их применение, фармацевтическая композиция и способ лечения
EP1559715B1 (en) N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
JP7168447B2 (ja) ビラスチンの結晶形態及びそれらの調製方法
JP2022530441A (ja) 7h-ピロロ[2,3-d]ピリミジンjak-阻害剤
TWI246512B (en) Eletriptan hydrobromide monohydrate as 5-HT1B/1D receptor agonist, pharmaceutical composition containing the same, and preparation method thereof
CN111278808B (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
EP2542548A1 (en) Process for preparation of polymorphic form and new polymorphic form of imatinib mesylate isolated in that process
KR100573635B1 (ko) 형태 Ⅵ의 5,6-디클로로-2-(이소프로필아미노)-1-(β-L-리보푸라노실)-1H-벤즈이미다졸
SK12697A3 (en) Polymorphs of lesopitron dichlorochloride and its hydrated forms, preparation method and compositions containing them
KR20190056398A (ko) 무스카린 아세틸콜린 수용체 작용제의 결정성 다형체
JP2018518515A (ja) フェニルアミノピリミジン化合物またはその塩の多形物
EA001715B1 (ru) Гидрат n-(4-ацетил-1-пиперазинил)-4-фторбензамида
AU2004232495B2 (en) 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo [2, 3d]pyrimidine hydrogen mesylate and its polymorphic forms
WO2024217521A1 (zh) 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物枸橼酸盐的晶型、制备方法及其应用
WO2024179463A1 (zh) 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法
ZA200302520B (en) Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl] piperazine.hydrochloride.
DE69809564T2 (de) 2- 4-[4-(4,5-dichlor-2-methylimidazol-1-yl)butyl]piperazin-1-yl -5-fluorpyrimidin, seine herstellung und therapeutische verwendung
DE10260618B4 (de) Tumorhemmende annellierte Azepinonderivate
NL8700233A (nl) Tetracyclische chinazolinonen.